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Introduction
Ovarian cancer reached 230,555 cases and accounted for 141,452 deaths worldwide in 2007, constituting 4.0% of all female cancers and 4.3% of cancer deaths in women (1). More than 70% of patients with ovarian cancer are diagnosed at the advanced stage (2) . Currently, standard primary therapy for advanced disease involves combining maximal cytoreductive surgery with chemotherapy consisting of carboplatin and paclitaxel (3, 4) . Though this treatment regimen initially yields a high response rate, more than 70% of patients relapse and develop resistance to platinum and taxane (2, 5) . Moreover, an international study, GOG 182-ICON5, sought to improve the efficacy of standard carboplatin-paclitaxel therapy by incorporating newer cytotoxic agents (gemcitabine, pegylated liposomal doxorubicin, topotecan) in sequential doublet and triplet combinations. Unfortunately, no combination of the several agents used in standard therapy has improved overall survival (3) . Alternate chemotherapeutic agents, such as pegylated liposomal doxorubicin, topotecan, gemcitabine, and etoposide, usually are used to treat recurrent ovarian cancers (6) (7) (8) (9) . However, these agents generally result in low response rates, approximately 15 to 30%, and poor survival. Thus, effective and novel treatment strategies (e.g. incorporation of molecular-targeted agents) for advanced ovarian cancer are needed urgently.
Activating the phosphatidylinositol 3'-kinase (PI3K) /Akt pathway and its downstream signaling mammalian target of rapamycin (mTOR) appears to indicate drug resistance and poor prognosis in many cancers and, therefore, may be an attractive target for therapy (10) (11) (12) . In ovarian cancer amplified PI3K and activated Akt have been found in 12 to 68% of tumors and were associated closely with the up-regulation of mTOR signaling (10) (11) (12) . mTOR was differentiated to two complexes: mTOR complex 1 (mTORC1) and mTORC2. mTORC1
regulates protein synthesis by directly phosphorylating the eukaryotic initiation factor 4E-binding protein 1 (4E-BP1) and also affects the activity of p70 S6 kinase (S6K1), and leads to cell growth and G1 cell cycle progression (13) (14) (15) . mTORC2 has been shown to be an upstream regulator of Akt, whereas mTORC1 acts downstream of Akt, and the activity is up-regulated by compensatory response to mTORC1 down-regulation in certain circumstances (13) . Therefore, inhibition of mTOR seems to be a candidate for therapy in patients with ovarian cancer.
Rapamycin, one of the mTOR inhibitors, was first isolated from the soil bacterium Streptomyces hygroscopicus in the 1970's (16) . It belongs to the class of macrolide antibiotics and was originally developed as an antifungal and immunosuppressant agent. Then it was found to have potent antiproliferative properties in a variety of solid tumors (17) . Rapamycin binds to a member of the immunophilin protein family, FK506 binding protein 12 (FKBP12), and the complex inhibits kinase activity of mTOR by directly binding mTORC1. When the downstream signaling of mTOR, such as 4E-BP and S6K1, is blocked it leads to arrest in the G1 phase cell cycle and apoptosis (18) . Several clinical trials also have shown potential antitumor activities of rapamycin and its derivatives everolimus (RAD001), deforolimus (AP23573), and temsirolimus (CCI779) in solid tumors, including ovarian cancer (19) .
Recently, rapamycin has been reported to enhance the effects of a variety of chemotherapeutic agents in several types of cancer (20) (21) (22) (23) . However, the effects of mTOR inhibitors combined with the range of cytotoxic agents have not been evaluated systematically in ovarian cancer. We conducted the present study to determine whether rapamycin enhances the effects of anticancer agents (cisplatin, paclitaxel, etoposide, doxorubicin, camptothecin, and gemcitabine) used as first-and second-line chemotherapy to treat ovarian cancer. We also explored the mechanisms of the synergistic interaction between rapamycin and these agents.
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Materials and Methods
Cell lines and culture conditions. The six human ovarian serous adenocarcinoma cell lines (KF, KOC-2S, SHIN-3, SK-OV-3, TU-OS-3 , TU-OS-4) used in this study were obtained as follows: KF, from Dr Yoshihiro Kikuchi (National Defense Medical College, Tokorozawa, Japan); KOC-2S, from Dr Toru Sugiyama (Kurume University, Kurume, Japan); and SHIN-3, from Dr Yasuhiko Kiyozuka (Nara Medical University, Kashihara, Japan). SK-OV-3 came from the American Type Culture Collection (Manassas, VA, USA). TU-OS-3 and TU-OS-4 were established by our department. These cell lines were maintained in D-MEM/Ham's F-12 medium (Wako, Osaka, Japan) with 10% fetal bovine serum, 100 IU/mL penicillin and 50 μm/mL streptomycin in a humidified atmosphere containing 5% CO 2 at 37°C.
Dose-response studies. The sensitivity of the cell lines to the anticancer agents was determined by a cytotoxicity assay using Cell Counting Kit-8 (Dojindo Laboratories, Kumamoto, Japan), according to the specifications of the manufacturer. Briefly, cells were diluted with culture medium to a seeding density of 1 to 5 × 10 4 cells/mL, plated on 96-well tissue culture plates at 180 μL/well (Sumitomo Bakelite, Tokyo, Japan), and incubated at 37°C overnight. The next day the cells were treated continuously with 20 μL of various concentrations of the anticancer agents to obtain a dose-response curve for each agent. Concentration for each drug were: 0.05 to 50 μM rapamycin (BIOMOL Research Laboratories Inc., PA, USA); 0.025 to 64 μM etoposide (BioVision, Inc., CA, USA); 0.015 to 3 μg/mL doxorubicin (Sigma, St. Louis, MO, USA); 7-ethyl-10-hydroxycamptothecin (SN-38) (Yakult Honsha Co., Tokyo, Japan), which is an active metabolite of CPT-11; 0.02 to 8 μM gemcitabine (LKT Laboratories, Inc., MN, USA); 1 to 30 μM cisplatin (Sigma); and 1 to 500 nM paclitaxel (Sigma). After being incubated for 72 h, 20 μL of Cell Counting Kit-8 solution was added to each well, and the plates were incubated for were calculated using the Kaplan-Meier method, and the significance of apparent differences in survival distribution between groups was tested with log-rank tests. A P value < 0.05 was considered statistically significant.
Results
Sensitivity to anticancer agents. We sought to determine the effect of cell proliferation for five first-and second-line chemotherapeutic drugs commonly used to treat ovarian cancer.
Growth inhibition was measured three days after exposure to the anticancer agents using Cell Counting Kit-8. The IC 50 values of six ovarian cancer cell lines to the anticancer agents are shown in Table I . IC 50 showed varied sensitivities to these agents: 0.14 to 50 μM for etoposide, 17 to 3800 ng/mL for doxorubicin, 15 to 310 nM for SN-38, 0.12 to 28 μM for gemcitabine, 3.3 to 25 μM for cisplatin, and 22 to 570 nM for paclitaxel.
Combination effects of rapamycin and anticancer agents. We next analyzed the synergistic activity of combining rapamycin with each anticancer agent by calculating CI values using the method of Chou and Talalay (24) . Data representative of rapamycin combined with etoposide in KF cells is shown in figure 1A . The CI value at an effective dose of 50 (effective dose means the percentage inhibition of cell growth using the drug combinations in the actual experiment) was less than 0.9 (synergism) for five cell lines for etoposide, four cell lines for doxorubicin, and two cell lines for SN-38 (Fig. 1B) . However, the CI value was more than 1.1 (antagonism) for three cell lines for gemcitabine, five cell lines for cisplatin, and four cell lines for paclitaxel. Rapamycin combined with etoposide had a synergistic effect in the greatest number of cell lines.
We then assessed the colony-forming capacity by a soft agar assay to determine whether the clonogenic growth of ovarian cancer cells also was reduced by rapamycin combined with etoposide. At 7 days after exposure the colony-forming capacity was reduced significantly by this combination in KF and SK-OV-3 cells (Fig. 2 ).
Rapamycin combined with etoposide up-regurates c-Jun and the apoptotic pathway.
Because the CI value was less than 1 for all six cell lines when etoposide was combined with rapamycin we examined whether the synergism arose from an increase in apoptosis induced by etoposide. The level of PTEN, phosphorylated (p) Akt, pmTOR, p4E-BP1, and pS6K1 proteins expressed were confirmed in all cell lines (data not shown). Bax and pc-Jun proteins increased after treatment with etoposide in KF and SK-OV-3 cells (Fig. 3A, B) . Interestingly, 24 h after being treated with etoposide and rapamycin the protein expression of pc-Jun increased dramatically and Bcl-xL was down-regulated, although Bcl-2 was not affected after exposure. Finally, to determine whether the synergistic effect of combining rapamycin with etoposide was caused by up-regulation of the c-Jun pathway, we examined cell viability after treatments with etoposide and with or without both rapamycin and SP600125 or each individually. At two days after exposure inhibition of cell growth and apoptosis were measured using the in vitro cytotoxicity assay and annexin V staining, respectively. Etoposide combined with rapamycin dramatically suppressed cell growth (P < 0.05, Fig. 4A ) and increased the number of apoptotic cells in KF and SK-OV-3 cell cultures (P < 0.05, Fig. 4B, 4C ). However, cells in which the c-Jun
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on (Fig. 5A ). There were no signs of overt toxicity (weight loss or gross clinical signs) in any group (Fig. 5B) . In nude mice bearing KF the mean tumor weight of tumors disseminated peritoneally in the group treated with rapamycin combined with etoposide (0.12 ± 0.04 g) was significantly lower than that of the group treated with PBS (1.42 ± 0.45 g), rapamycin alone (0.68 ± 0.08 g), or etoposide alone (0.62 ± 0.15 g) (P < 0.05). Similarly, in nude mice bearing SK-OV-3 the mean tumor weight of tumors disseminated in the peritoneum in the group treated with rapamycin combined with etoposide (0.24 ± 0.11 g) was significantly lower than that of the group treated with PBS (1.96 ± 0.59 g), rapamycin alone (1.10 ± 0.37 g), or etoposide alone (0.98 ± 0.18 g) (P < 0.05). In nude mice bearing KF the median survival times were 61 days for rapamycin treatment, 64 days for etoposide, 98 days for rapamycin with etoposide, and 50 days for PBS. Mice treated with etoposide combined with rapamycin survived significantly longer than those treated with PBS, rapamycin, or etoposide alone (P < 0.001, Fig. 5D ). Similarly, in nude mice bearing SK-OV-3 the median survival times were 95 days for rapamycin treatment, 98 days for etoposide, 174 days for rapamycin with etoposide, and 77 days for PBS. Mice treated with etoposide combined with rapamycin survived significantly longer than those treated with PBS, rapamycin, or etoposide alone (P < 0.001, Fig. 5E ). These findings indicate that combining etoposide and rapamycin prolonged survival in nude mice bearing KF or SK-OV-3 cells. (19, 25) . The present study aimed to determine the best therapy to combine the mTOR inhibitor rapamycin with six cytotoxic agents (etoposide, doxorubicin, camptothecin, gemcitabine, cisplatin, paclitaxel) used commonly to treat ovarian cancer. We found rapamycin and etoposide had the strongest cytotoxic effect. The effectiveness of the combination was confirmed in ovarian cancer xenograft models. Combining rapamycin and etoposide prolonged the survival of these mice compared with those treated by rapamycin or etoposide alone. These data provide clear evidence that this combination may be effective for ovarian cancer. To our knowledge, this was the first study to show that rapamycin combined with etoposide was effective against ovarian cancer, both in vitro and in vivo, and explored the mechanisms of synergistic interaction between these drugs.
The Akt/mTOR signaling pathway plays a central role in cell growth, proliferation, and apoptosis. The activity of this pathway frequently is elevated in several cancers, including ovarian cancer (10) (11) (12) . Loss of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) and activation of Akt have been associated closely with the up-regulation of mTOR signaling and result in hypersensitivity to mTOR inhibitors (26, 27) . Recently, Mondesire, et al., (20) reported that rapamycin synergistically enhanced apoptosis induced by paclitaxel and carboplatin only in cells sensitive to rapamycin. Mabuchi, et al., (28) also reported that the rapamycin analog RAD001 enhanced cisplatin-induced apoptosis in ovarian cancer cells (SK-OV-3 and OVCAR10) with high Akt/mTOR activity, whereas a minimal effect was seen in cells with low Akt/mTOR activity. Similarly, we observed the synergistic effect of rapamycin and Furthermore, no synergistic effects were seen when rapamycin was combined with paclitaxel in all six cell lines tested. We found previously that simultaneous inhibition of the mitogen-activated protein kinase kinase and Akt pathways was necessary to enhance sensitivity to paclitaxel in ovarian cancer cells (29) . These results suggested that the combination effects of rapamycin with cisplatin or paclitaxel, both of which are used for first-line chemotherapy, might be limited for treatment of patients with ovarian cancer.
Patients who relapse within 6 months after first-line chemotherapy ends have a form of the disease that is likely to resist platinum agents and taxane compounds. Therefore, a topoisomerase I inhibitor (topotecan), a topoisomerase II inhibitor (etoposide, pegylated liposomal doxorubicin), and a pyrimidine analogue (gemcitabine) are used commonly for second-line chemotherapy in these patients (6) (7) (8) (9) . Among these agents we found additive or synergistic effects of topoisomerase I or II inhibitors combined with rapamycin in all six cell lines tested. The combination of rapamycin and etoposide led to especially synergistic effects on five out of six cell lines regardless of the levels at which the pAkt and pmTOR proteins were expressed. This set of results suggested that rapamycin enhances the cytotoxicity induced by etoposide independently of AKT/mTOR activity and that this combination may be an effective treatment for ovarian cancer.
Several studies have reported on the synergic interaction between rapalogues and etoposide in hematologic tumors, but the mechanisms of this interaction have not been shown (30, 31) .
Etoposide has been shown to activate JNK, and this is thought to correlate with induced cell death (32, 33) . Indeed, apoptosis induced by etoposide was lower in combination with the JNK inhibitor, SP600125, though this effect was not statistically significant. Rapamycin also has been shown to induce rapid and sustained activation of apoptosis signal-regulating kinase 1, JNK; and to elevate pc-Jun, resulting in apoptosis (34) . Therefore, the combination of rapamycin with etoposide may induce further activation of the c-Jun signaling pathway. The mechanism by which JNK promotes apoptosis is thought to involve potentiation of release of mitochondrial cytochrome c, which cleaves caspase 9 or inactivates anti-apoptotic proteins, such as Bcl-2 and Bcl-xL (35) (36) (37) . These evidences support our findings from western blot analysis that up-regulation of pc-Jun, cleaved caspase 9 and down-regulation of Bcl-xL were observed after rapamycin was combined with etoposide to treat ovarian cancer cells. Further, inhibition of JNK by SP600125 attenuated apoptosis induced by this drug combination. Our findings suggested that the JNK pathway has a key role in the synergistic induction of apoptosis by the treatment of ovarian cancer cells with rapamycin and etoposide together.
Sustained activation of the JNK cascade and apoptosis by rapamycin are suppressed by wild-type p53, where the cells are arrested in the G1 phase (34) . However, the effect of rapamycin on cytotoxicity induced as chemotherapy was observed in both p53 mutant and p53 wild-type breast cancer cells (20) . We also found a synergistic interaction in both p53 wild-type 
for 21 days, every 28 days. The maximum serum etoposide concentration (Cmax) after intra-venous injection and oral administration reaches 25.8 μM and 5.8 μM (at Day 1) to 7.8 μM (at Day 21) every treatment day, respectively (38) (39) (40) . The IC 50 value of KF cell line for etoposide was 30 μM, but a significant synergistic effect was seen in combination with rapamycin and 4 or 8 μM etoposide. Furthermore, it is reported that the Cmax of the mice after 10 mg/kg intra-venous treatment is 54.5 μM, though the Cmax after intra-peritoneal injection is not available (41) . Thus, the dose of etoposide in our experiment is roughly equivalent to the standard clinical dose used in patients.
In summary, our study showed that the mTOR inhibitor rapamycin enhanced the cytotoxicity of some chemotherapeutic agents, especially etoposide, in ovarian cancer cells. We also found that the synergistic interaction of rapamycin and etoposide may be related to up-regulation of the pc-Jun protein that results in induction of apoptosis. Furthermore, this combined treatment prolonged the survival of nude mice injected with ovarian cancer cells. Therefore, we concluded that combining rapamycin with etoposide is worth exploring as a treatment for ovarian cancer.
We hope that this combination therapy will improve the survival of patients with advanced ovarian cancer.
